News >

Larotrectinib Exceeds 90% Response Rate in TRK+ Pediatric Cancers

Jason Harris
Published: Tuesday, Apr 03, 2018

Theodore W. Laetsch, MD

Theodore W. Laetsch, MD
Larotrectinib induced an “unprecedented” objective response rate of 93% in pediatric patients with TRK fusion–positive solid tumors, according to findings from a phase I/II study published in The Lancet Oncology.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication